VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine

Summary

This is an open label, single-site, first-in-human, Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs25-IMX313 in Matrix-M1 adjuvant in healthy adults living in the UK Volunteers will receive 3 doses of vaccine over 2 months and will be followed up for approximately 8 months.

Timeline

Start

2019-09-27

Primary completion

2020-09-22

Completion

2020-09-22

Drugs

Indications